ABSTRACT
The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study (N Engl J Med 2006; 354:1706–1717, J Am Coll Cardiol 2007; 49:1982–1988) assessed the effect of dual antiplatelet therapy with clopidogrel (Plavix) and aspirin in patients at risk of atherothrombotic events. At a median of 28 months, the rate of the primary efficacy end point (a composite of myocardial infarction, stroke, and death from cardiovascular causes) was not significantly lower in the group receiving clopidogrel plus aspirin than in the group receiving placebo plus aspirin. However, one subgroup may have derived some benefit from the combination: those at higher risk owing to a history of myocardial infarction, ischemic stroke, or symptomatic peripheral arterial disease.
Footnotes
↵* Dr. Bhatt has disclosed that he or his department has received research support (which was conveyed directly to the institution), honoraria, or consulting fees (which were donated to nonprofit organizations) from Abraxis, Alexion Pharma, Astellas, AstraZeneca, Atherogenics, Aventis, Biosense Webster, Biosite, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, Cardionet, Centocor, Cogentus, Converge Medical Inc., Cordis, Daiichi-Sankyo, Dr. Reddy’s, Edwards Lifesciences, Eisai, Eli Lilly, Esperion, Ethicon, GE Medical Genentech, Gilford, Glaxo SmithKline, Guidant, Heartscape, Johnson & Johnson, Kensey-Nash, McNeil, MedTronic, Merck, Millennium, Mytogen, Novartis, Novo Nordisk, Orphan Therapeutics, Otsuka, Paringenex, PDL, Portola, Procter and Gamble Pharma, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, Scios, St. Jude Medical, Takeda, The Medicines Company, tns Healthcare, VasoGenix, Vertex, and Viacor.
- Copyright © 2008 The Cleveland Clinic Foundation. All Rights Reserved.